# Orlistat Overcoming Third-generation EGFR-TKI Resistance

> **NCT06818955** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ping Peng** · enrollment: 36 (estimated)

## Conditions studied

- Lung Adenocarcinoma
- Osimertinib

## Interventions

- **DRUG:** Orlistat 120 mg

## Key facts

- **NCT ID:** NCT06818955
- **Lead sponsor:** Ping Peng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-16
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-11-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06818955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06818955, "Orlistat Overcoming Third-generation EGFR-TKI Resistance". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06818955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*